Ortho Clinical Diagnostics Names Evelyn Dilsaver to Board of Directors

Rhea-AI Summary

Ortho Clinical Diagnostics announced the appointment of Evelyn Dilsaver to its board of directors and as audit committee chair. Dilsaver, who previously served as CEO of Charles Schwab Investment Management, brings extensive financial experience, having grown the firm's assets significantly. She holds multiple board positions and has received various prestigious awards for her leadership. Dilsaver expressed enthusiasm about contributing to Ortho during its growth phase as a public company, emphasizing the company’s pivotal role in clinical diagnostics.

Positive

• Evelyn Dilsaver's extensive financial expertise may enhance strategic decision-making.
• Dilsaver's experience in growing assets at Charles Schwab could provide valuable insights for Ortho.

Negative

• Concerns about continuity and experience gaps as a new leader is introduced.

Former CEO of Charles Schwab Investment Management will also serve as audit committee chair

RARITAN, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care, today announced that Evelyn Dilsaver, former CEO of Charles Schwab Investment Management, has been appointed as a member of its board of directors and will serve as audit committee chair.

Dilsaver served as the president and CEO of Charles Schwab Investment Management, the mutual fund arm of The Charles Schwab Corp. ($3.25 trillion assets under management), from 2004 to 2007, during which time she successfully grew the business from $132 billion to more than $200 billion in assets. She also served in various leadership roles at Schwab for more than 16 years, including controller and chief of staff to the co-CEO. Dilsaver began her career at Ernst & Young, where she specialized in the banking and savings and loan industries. 

A celebrated businesswoman, Dilsaver received the NACD 100 Directorship Award (2020), was named “Outstanding Director” (2014), received the “Forever Influential Award” (2010) and was named as one of the “100 Most Influential Women” (2004-2009) by the San Francisco Business Times.

“Evelyn is a recognized leader in her field and is known for her strategic vision and financial acumen,” said Chris Smith, chairman and chief executive officer, Ortho. “As we enter our next phase of growth and evolution, we believe her deep financial expertise and broad leadership experience will greatly benefit Ortho.”

Dilsaver holds several corporate board of director positions, including Blue Shield of California (2009 – present), TempurSealy (NYSE: TPX) (2009 – present), Protiviti (2013 – present), Health Equity (Nasdaq: HQY) (2014 – present) and Bailard Real Estate Investment Fund (2015 – present). She also serves as a board member of several nonprofit organizations, including Blue Shield Foundation (2014 – present) and The Commonwealth Club (2008 – present). Dilsaver’s previous board positions include Aeropostale Inc., High Mark Funds and the Russell ETF. 

She earned her Bachelor of Science degree in accounting from California State University – Hayward and completed the Stanford Senior Executive Program in 1996. She was awarded an honorary Doctor of Humane Letters from Cal State East Bay in 2016.

“Ortho Clinical Diagnostics is at the epicenter of the evolution in clinical diagnostic testing and is well positioned to continue making its mark during this pivotal time in the industry,” Dilsaver said. “I look forward to contributing to the board’s work, particularly as the company begins its next phase of operations as a public company.”

About Ortho Clinical Diagnostics

Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world’s largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.

More than 800,000 patients across the world are impacted by Ortho’s tests each day. Because Every Test is a Life™, Ortho provides hospitals, hospital networks, clinical laboratories and blood banks around the world with innovative technology and tools to ensure test results are fast, accurate, and reliable. Ortho's customized solutions enhance clinical outcomes, improve efficiency, overcome lab staffing challenges and reduce costs.

From launching the first product to determine Rh+ or Rh- blood type, developing the world’s first tests for the detection of antibodies against HIV and hepatitis C, introducing patented dry-slide technology and marketing the first U.S. Food and Drug Administration-authorized high-volume antibody and antigen tests for COVID-19, Ortho has been a pioneering leader in the IVD space for over 80 years.

The company is powered by Ortho Care™, an award-winning, holistic service and support program that ensures best-in-class technical, field and remote service and inventory support to laboratories in 130 countries around the globe.  

For more information, visit Ortho’s website or social media channels: LinkedIn, Twitter, Facebook and YouTube. 

Media Contact:
Elaine Colón
Ortho Media Relations
M: +1 908 295 1579
media@orthoclinicaldiagnostics.com

FAQ

Who is Evelyn Dilsaver and what is her role at Ortho Clinical Diagnostics?

Evelyn Dilsaver is the newly appointed board member and audit committee chair at Ortho Clinical Diagnostics, bringing significant financial expertise from her leadership at Charles Schwab Investment Management.

What impact could Dilsaver's appointment have on the future of OCDX?

Dilsaver's financial acumen and strategic vision are expected to benefit Ortho Clinical Diagnostics as it navigates its next growth phase as a public company.

When did Evelyn Dilsaver join the board of Ortho Clinical Diagnostics?

Evelyn Dilsaver was appointed to the board of Ortho Clinical Diagnostics on February 23, 2021.